Exact Mass: 706.1395

Exact Mass Matches: 706.1395

Found 26 metabolites which its exact mass value is equals to given mass value 706.1395, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

6)-glucoside]

3,5,7,4-Tetrahydroxyflavone 3- [ 2",3",4"-triacetyl-alpha-L-arabinopyranosyl- (1->6) -glucoside ]

C32H34O18 (706.1745)

6)-glucoside

Kaempferol 3-[2,3,5-triacetyl-alpha-L-arabinofuranosyl-(1-

C32H34O18 (706.1745)

subulatin

C32H34O18 (706.1745)

An alkyl caffeate ester isolated from Lophocolea heterophylla and Jungermannia subulata and has been shown to exhibit antioxidant activity.

Kaempferol 3-[2,3,4-triacetyl-alpha-L-arabinopyranosyl-(1->6)-glucoside]

C32H34O18 (706.1745)

Kaempferol 3-[2,3,5-triacetyl-alpha-L-arabinofuranosyl-(1->6)-glucoside

C32H34O18 (706.1745)

rel-(1S,2R,3R,5S,7R)-7-[(E)-caffeoyloxymethyl]-2,3-di[(E)-caffeoyloxy]-6,8-dioxabicyclo[3.2.1]octane-5-carboxylic acid

C35H30O16 (706.1534)

PLC Thio-PIP2

3-(3-(1,2-dihydroxy-1,2-dihexanoyl)thiopropane)inositol-4,5-diphosphate, trisodium salt

C21H41O18P3S (706.1226)

calcium,3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

C32H34CaN4O8S2 (706.1444)

W-84 (dibromide) is a potent allosteric modulator of M2-cholinoceptors, which retards [3H]N-methylscopolamine dissociation. W-84 dibromide can stabilize cholinergic antagonist-receptor complexes. W-84 (dibromide) is a non-competitive muscarinic acetylcholine receptors antagonist with allosteric effects. W-84 (dibromide) protects over additively against an organophosphate-intoxication when applied in combination with atropine[1][2][3].

disodium 3,3-[(9,10-dihydro-9,10-dioxo-1,4-anthrylene)bis[imino(3-methylpropane-1,3-diyl)]]bis(benzenesulphonate)

C34H32N2Na2O8S2 (706.1395)

3-(3-(1,2-Dihydroxy-1,2-dihexanoyl)thiopropane)inositol-4,5-diphosphate

C21H41O18P3S (706.1226)

Heme d1

C34H26FeN4O10-6 (706.0998)

7-(4-hydroxy-3,5-dimethoxyphenyl)-11-oxo-6-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxymethyl]oxan-2-yl]oxy-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaene-3-carboxylic acid

7-(4-hydroxy-3,5-dimethoxyphenyl)-11-oxo-6-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxymethyl]oxan-2-yl]oxy-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaene-3-carboxylic acid

C35H30O16 (706.1534)

ferroheme d1(4-)

C34H26FeN4O10 (706.0998)

A cyclic tetrapyrrole anion arising from deprotonation of the four carboxy groups of ferroheme d1; major species at pH 7.3.

ACG416B

C38H36Br2N4 (706.1307)

ACG416B (compound 18) is a potent inhibitor of ChoK (choline kinase) with an IC50 of 0.4 μM. ACG416B renders higher ChoK inhibitory and antiproliferative activities against the HT-29 human colon cancer cell[1].

[(2r,3s,4r,5r)-3,4-bis(acetyloxy)-5-{[(2s,3s,4r,5s,6s)-6-{[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methoxy}oxolan-2-yl]methyl acetate

C32H34O18 (706.1745)

(3s,5as,6s,10ar)-3-{[(3s,5as,6s,10ar)-6-(acetyloxy)-3-hydroxy-3-(hydroxymethyl)-2-methyl-1,4-dioxo-5ah,6h,10h-pyrazino[1,2-a]indol-10a-yl]disulfanyl}-10a-hydroxy-3-(hydroxymethyl)-2-methyl-1,4-dioxo-5ah,6h,10h-pyrazino[1,2-a]indol-6-yl acetate

(3s,5as,6s,10ar)-3-{[(3s,5as,6s,10ar)-6-(acetyloxy)-3-hydroxy-3-(hydroxymethyl)-2-methyl-1,4-dioxo-5ah,6h,10h-pyrazino[1,2-a]indol-10a-yl]disulfanyl}-10a-hydroxy-3-(hydroxymethyl)-2-methyl-1,4-dioxo-5ah,6h,10h-pyrazino[1,2-a]indol-6-yl acetate

C30H34N4O12S2 (706.1615)

6-(1,2-dihydroxyethyl)-5-{[3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4-{[3-(3-hydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)prop-2-enoyl]oxy}-5,6-dihydro-4h-pyran-2-carboxylic acid

6-(1,2-dihydroxyethyl)-5-{[3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4-{[3-(3-hydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)prop-2-enoyl]oxy}-5,6-dihydro-4h-pyran-2-carboxylic acid

C32H34O18 (706.1745)

[3,4-bis(acetyloxy)-5-[(6-{[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl)methoxy]oxolan-2-yl]methyl acetate

C32H34O18 (706.1745)

4,5-bis(acetyloxy)-2-[(6-{[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl)methoxy]oxan-3-yl acetate

C32H34O18 (706.1745)

(2r,3r,4s,5s)-4,5-bis(acetyloxy)-2-{[(2r,3s,4s,5r,6s)-6-{[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methoxy}oxan-3-yl acetate

C32H34O18 (706.1745)

(4r,5r,6r)-6-[(1r)-1,2-dihydroxyethyl]-5-{[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4-{[(2e)-3-(3-hydroxy-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)prop-2-enoyl]oxy}-5,6-dihydro-4h-pyran-2-carboxylic acid

(4r,5r,6r)-6-[(1r)-1,2-dihydroxyethyl]-5-{[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4-{[(2e)-3-(3-hydroxy-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)prop-2-enoyl]oxy}-5,6-dihydro-4h-pyran-2-carboxylic acid

C32H34O18 (706.1745)

[(2s,3s,4r,5r)-3,4-bis(acetyloxy)-5-{[(2r,3s,4s,5r,6s)-6-{[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methoxy}oxolan-2-yl]methyl acetate

C32H34O18 (706.1745)

(5r,6r,13s,21r)-5,13-bis(3,4-dihydroxyphenyl)-9,17,19,21-tetrahydroxy-4,12,14-trioxapentacyclo[11.7.1.0²,¹¹.0³,⁸.0¹⁵,²⁰]henicosa-2,8,10,15,17,19-hexaen-6-yl (2e)-3-phenylprop-2-enoate

C39H30O13 (706.1686)